ArticleACS synthetic biology2025
Direct Modeling of DNA and RNA Aptamers with AlphaFold 3: A Promising Tool for Predicting Aptamer Structures and Aptamer-Target Interactions.
Article in ACS synthetic biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Evolutionary Dynamics-AwareACS omega · 2026Article
- Molecular Engineering of Aptamers for Glioblastoma Therapy: From Simple Antagonists to AI-Driven Approaches, a Narrative Review.International journal of molecular sciences · 2026Review
- Nucleic acid aptamers: new methods for selection, target validation, molecular diagnostics and therapeutics.Signal transduction and targeted therapy · 2026Review
- Metabolic disease variants rewire gene regulation through disruption of DNA G-quadruplex structures.Genome biology · 2026Article
- Article
- Swine GBP1 restricts PDCoV replication via disrupting the replication and transcription complex formation.Journal of virology · 2026Article
- Comprehensive evaluation of artificial intelligence-empowered approaches for protein-aptamer complex prediction.Briefings in bioinformatics · 2026Article
- Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1.Journal of nanobiotechnology · 2026Article
- In silico aptamer design: from sequence selection to structural optimization and computational modelling strategies.Journal of computer-aided molecular design · 2026Review
- Predicting Single-Stranded DNA Oligonucleotides 3D Structures: An Open Issue.Computational and structural biotechnology journal · 2026Article
- Aptamer Engineering: Strategies for Discovering Functional Nucleic Acids for Next-Generation Diagnostics and Biosensing.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Sequence optimization of a DNA aptamer inhibiting COVID-19 infection guided by analysis of secondary structure distribution.Computational and structural biotechnology journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamers, single-stranded nucleic acids that fold into unique three-dimensional shapes, bind selectively to non-nucleotide target molecules, making them promising ligands for diagnostic and therapeutic applications. The ability to accurately predict folded aptamer structures and their molecular interactions would significantly enhance the rational design of nucleic acid-based affinity reagents. However, predicting the 3D structures of aptamers remains challenging due to their complex folding patterns and limited experimental structure data compared to proteins. AlphaFold 3 is the latest structure prediction tool by Google DeepMind that has recently expanded to include nucleic acids and small molecule targets, offering new possibilities for the direct 3D modeling of aptamer sequences. This study evaluates the accuracy of AlphaFold 3 by comparing its predictions to experimentally resolved aptamer structures in the Protein Data Bank (PDB) and to well-characterized aptamers not included in the PDB. AlphaFold 3 effectively modeled a range of PDB-resolved aptamer structures, including those with noncanonical secondary structure elements such as G-quadruplexes and pseudoknots. For non-PDB aptamers, AlphaFold predictions were considerably less confident yet showed reasonable overlap with experimental data, accurately predicting G-quadruplex conformations and, in some cases, correctly localizing known binding interfaces in aptamer-protein complexes. Despite these attributes, AlphaFold 3 predictions appear limited by biases in its training data, reflecting the relative scarcity and redundancy of nongenomic nucleic acid structures in the PDB. These findings highlight the potential of AlphaFold 3 for aptamer modeling but underscore the need for further refinement to reliably predict complex, underrepresented structures. AlphaFold 3 represents a powerful step toward in silico aptamer design and offers a promising glimpse into a future where artificial intelligence accelerates discoveries and advancements in aptamers as effective affinity reagents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.